Literature DB >> 28639722

European guideline for the management of scabies.

C M Salavastru1, O Chosidow2, M J Boffa3, M Janier4, G S Tiplica5.   

Abstract

Scabies is caused by Sarcoptes scabiei var. hominis. The disease can be sexually transmitted. Patients' main complaint is nocturnal itch. Disseminated, excoriated, erythematous papules are usually seen on the anterior trunk and limbs. Crusted scabies occurs in immunocompromised hosts and may be associated with reduced or absent pruritus. Recommended treatments are permethrin 5% cream, oral ivermectin and benzyl benzoate 25% lotion. Alternative treatments are malathion 0.5% aqueous lotion, ivermectin 1% lotion and sulphur 6-33% cream, ointment or lotion. Crusted scabies therapy requires a topical scabicide and oral ivermectin. Mass treatment of large populations with endemic disease can be performed with a single dose of ivermectin (200 micrograms/kg of bodyweight). Partner management needs a look-back period of 2 months. Screening for other STI is recommended. Patients and close contacts should avoid sexual contact until completion of treatment and should strictly observe personal hygiene rules when living in crowded spaces. Written information should be provided to suspected cases.
© 2017 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28639722     DOI: 10.1111/jdv.14351

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  30 in total

Review 1.  [85/m with scaly exanthema and itching : Preparation for the specialist examination: part 1].

Authors:  Christoph R Löser
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

2.  [Pseudo allergic reaction to metal implant].

Authors:  A Guertler; P Thomas; T Herzinger
Journal:  Hautarzt       Date:  2018-10       Impact factor: 0.751

3.  Ivermectin-a drug and a tool.

Authors:  Josef A I Weigl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-09       Impact factor: 3.267

4.  Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptes scabiei in the Porcine Scabies Model for Human Infestation.

Authors:  Charlotte Bernigaud; Fang Fang; Olivier Chosidow; Jacques Guillot; Katja Fischer; Anne Lespine; Ludwig S Aho; Amanda J Mullins; Berhane Tecle; Andrew Kelly; Jean-François Sutra; Francis Moreau; Thomas Lilin; Frédéric Beugnet; Françoise Botterel
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 5.  Scabies: Epidemiology, Diagnosis, and Treatment.

Authors:  Cord Sunderkötter; Johannes Wohlrab; Henning Hamm
Journal:  Dtsch Arztebl Int       Date:  2021-10-15       Impact factor: 8.251

6.  Risk factors associated with scabies infestation among primary schoolchildren in a low socio-economic area in southeast of Iran.

Authors:  Alireza Sanei-Dehkordi; Moussa Soleimani-Ahmadi; Mehdi Zare; Seyed Aghil Jaberhashemi
Journal:  BMC Pediatr       Date:  2021-05-25       Impact factor: 2.125

7.  Assessment of Knowledge and Fear of Scabies in a Saudi Population.

Authors:  Ahmad S Alharthi; Mohammed A Alsofyani; Wedd K Alharthi; Shaimaa A Alsalmi; Atheer S Altalhi; Khaled A Alswat
Journal:  J Multidiscip Healthc       Date:  2021-06-08

Review 8.  Ivermectin and permethrin for treating scabies.

Authors:  Stefanie Rosumeck; Alexander Nast; Corinna Dressler
Journal:  Cochrane Database Syst Rev       Date:  2018-04-02

9.  Recurrence of Classic Scabies in a Patient Who had Unchanged Tie String of the T-Cannula.

Authors:  Jiwon Jung; Jihye Jeong; Min Jee Hong; Eun Ok Kim; Min Jae Kim; Sung Eun Chang; Sung-Han Kim
Journal:  Infect Chemother       Date:  2021-12-02

10.  Importance of Follow-Up Microscopic Examination in Hospitalized Patients with Confirmed Scabies.

Authors:  Miseo Kim; Sun-Kyung Kim; Min Jee Hong; Sun Hee Kwak; Eun Ok Kim; Moonsuk Bae; Min Jae Kim; Woo Jin Lee; Sung-Han Kim; Jiwon Jung; Sung Eun Chang
Journal:  Am J Trop Med Hyg       Date:  2020-09-24       Impact factor: 3.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.